Dr. Reddy’s Receives Tentative FDA Approval for Lenacapavir

Dr. Reddy’s Laboratories received tentative approval from the U.S. Food and Drug Administration for a generic, twice-yearly injectable form of lenacapavir, according to Gktoday. Gktoday reported the FDA action on 2 November 2026.

FDA action reported by Gktoday

Gktoday described the regulatory decision as tentative approval. The report names Dr. Reddy’s Laboratories as the company receiving the action and the U.S. Food and Drug Administration as the agency involved.

The product identified in the report is a generic injectable form of lenacapavir. Gktoday characterized the administration schedule as twice yearly.

For medical and veterinary sales professionals tracking regulatory developments, the tentative designation is an important part of the reported event. The source does not describe the decision simply as an unqualified FDA approval.

Key details for customer discussions

• Company: Dr. Reddy’s Laboratories.
• Agency: U.S. Food and Drug Administration.
• Regulatory status: Tentative approval.
• Product: A generic injectable form of lenacapavir.
• Reported schedule: Twice yearly.

Why the designation matters

Accurate regulatory language can help field teams keep discussions aligned with the reported record. In this case, Gktoday’s account centers on a tentative FDA approval for the stated generic injectable lenacapavir product.

The report provides a defined set of details: the named manufacturer, the FDA as the cited regulator, the generic status, injectable dosage form, and twice-yearly schedule. It also identifies 2 November 2026 as the date of the reported FDA action.

Sales professionals discussing the update can distinguish the product description from the regulatory designation by referring to Gktoday’s wording: Dr. Reddy’s Laboratories received tentative approval for a generic, twice-yearly injectable form of lenacapavir.